Effects of trimetazidine on ischemic left ventricular dysfunction in patients with coronary artery disease

Lu, Chunzeng; Dąbrowski, Paweł; Fragasso, Gabriele; Chierchia, Sergio

doi:10.1016/s0002-9149(98)00500-1

Cited by 80 publications

(41 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A significant improvement in ejection fraction was also found with TMZ, compared with placebo, in a group of patients undergoing PTCA (Brottier et al 1990;Birand et al 1998). Recent studies have found that TMZ protects from dobutamine-induced ischemia and improves resting ventricular function (Lu et al 1998;Belardinelli and Purcaro 2001).…”

Section: Discussionmentioning

confidence: 89%

Suppression of Angioplasty-Related Inflammation by Pre-Procedural Treatment with Trimetazidine

Kuralay

Altekin

Yazlar

et al. 2006

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

Percutaneous transluminal coronary angioplasty (PTCA) has been recognized as a reliable treatment procedure for acute reversible ischemia and reperfusion. Ischemic reperfusion cycle in PTCA leads to the systemic inflammation and extensive tissue injury by the production of reactive oxygen species including nitric oxide (NO) radicals. In patients with coronary artery disease, undergoing PTCA, the effects of trimetazidine (TMZ), a piperazine-derivative anti-anginal drug, were studied on several indirect markers of systemic inflammatory response: tumor necrosis factor-α (TNF-α ), C-reactive protein (CRP) and NO products (nitrite and nitrate). Patients (n = 11 each group) were untreated or pre-treated with TMZ (20 mg per orally three times a day), begun three days prior to PTCA, and marker levels were measured before the start of TMZ therapy (baseline), just before PTCA (0 hr), and 4, 24, and 48 hrs after PTCA. The baseline levels of markers were not significantly different between the untreated and pre-treated patients. In contrast, all parameters were lower in the TMZtreated group than those in the matched control group in the pre-and post-angioplasty periods. Interestingly, in the TMZ group, CRP and nitrite levels were significantly lower than in the control group at each time point of the pre-and post-angioplasty periods, but the TNF-α levels were significantly decreased only in the post-angioplasty period. Preprocedural treatment with oral TMZ for three days significantly suppressed the elevation of inflammatory markers before and shortly after PTCA. We suggest the usefulness of TMZ in preventing inflammatory cardiovascular events after PTCA.trimetazidine; percutaneous transluminal coronary angioplasty; C-reactive protein; nitric oxide; tumor necrosis factor-α .

show abstract

Section: Discussionmentioning

confidence: 89%

Suppression of Angioplasty-Related Inflammation by Pre-Procedural Treatment with Trimetazidine

Kuralay

Altekin

Yazlar

et al. 2006

Tohoku J. Exp. Med.

View full text Add to dashboard Cite

show abstract

“…Although a cytoprotective effect has recently been described in animal as well as human models of acute myocardial ischaemia [6,7] , it is unclear whether trimetazidine may improve contractility of dysfunctional myocardium adapted to a chronic reduction in blood flow.…”

Section: Trimetazidinementioning

confidence: 99%

Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischaemic cardiomyopathy

Belardinelli

2001

European Heart Journal

123

View full text Add to dashboard Cite

Background There is evidence that trimetazidine, an antiischaemic agent with a direct cytoprotective effect on the myocardium, is effective in stable angina. However, it is not clear whether trimetazidine can improve the mechanical efficiency of chronically dysfunctional myocardium, and whether this potentially beneficial effect can translate into improvements in left ventricular function as well as functional capacity.Methods Thirty-eight patients (52·7 8 years) with postnecrotic left ventricular dysfunction (ejection fraction: 33 5%) and multivessel coronary artery disease were studied. Patients were randomized into two matched groups. Group A received trimetazidine (20 mg three times daily) for 2 months, while group B received a placebo during the same period. The usual antianginal medications were not altered during the study. At baseline and after 2 months, all patients underwent low-dose dobutamine echocardiography (5-20 g . kg 1 . min 1 ), and a symptomlimited cardiopulmonary exercise test.Results On initial evaluation, systolic wall thickening score index, heart rate, systolic blood pressure and rate pressure product were similar at rest and peak dobutamine in both groups. However, at 2 months, group A patients had significant improvements in the rest and peak systolic wall thickening score index (13% and 20·7%, P<0·001) and ejection fraction (19·7% and 14·1%, P<0·001) without concomitant changes in heart rate and blood pressure. Peak VO 2 was also significantly increased in patients taking trimetazidine (15%, P=0·001 vs controls). ConclusionsIn patients with ischaemic cardiomyopathy, trimetazidine improves the contractile response of chronically dysfunctional myocardium to dobutamine without haemodynamic changes. This effect was associated with improvements in left ventricular function and peak VO 2 .

show abstract

“…Таким образом, уменьшение энергетических затрат на уровне всего организма может быть одним из главных механизмов, посредством которого три-метазидин способен улучшать симптомы и функцию ЛЖ у пациентов с СН. Клинические преимущества триметазидина при СН Небольшие рандомизированные клинические исследования (РКИ) продемонстрировали эффек-тивность триметазидина в улучшении функциональ-ного класса СН по классификации NYHA, переноси-мости физической нагрузки, качества жизни, ФВЛЖ и сердечных объемов у пациентов с систолической хронической СН [9,10,[50][51][52][53][54][55][56][57]. В таблице 1 обобщены характеристики и основные результаты главных кли-нических исследований триметазидина у пациентов с систолической СН.…”

unclassified

Rationale for Application, and Benefits of Trimetazidine in Heart Failure by Its Influence of Myocardium Metabolism

Lopatin¹,

Rosano²,

G³

et al. 2016

Russ J Cardiol

View full text Add to dashboard Cite

Effects of trimetazidine on ischemic left ventricular dysfunction in patients with coronary artery disease

Cited by 80 publications

References 6 publications

Suppression of Angioplasty-Related Inflammation by Pre-Procedural Treatment with Trimetazidine

Suppression of Angioplasty-Related Inflammation by Pre-Procedural Treatment with Trimetazidine

Effects of trimetazidine on the contractile response of chronically dysfunctional myocardium to low-dose dobutamine in ischaemic cardiomyopathy

Rationale for Application, and Benefits of Trimetazidine in Heart Failure by Its Influence of Myocardium Metabolism

Contact Info

Product

Resources

About